TY - JOUR
T1 - Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema
AU - Pressler, A.
AU - Grosber, M.
AU - Halle, M.
AU - Ring, J.
AU - Brockow, K.
PY - 2013/3
Y1 - 2013/3
N2 - Vibratory angio-oedema is a rare form of physical urticaria characterized by pruriginous weals and angio-oedema at the site of exposure to vibration. Severe treatment-resistant disease can occur, and is associated with significant disability. Therapy with omalizumab, a monoclonal IgG anti-IgE antibody, has been shown to be successful in several types of physical urticaria. We report a patient with vibratory angio-oedema for whom all standard treatments for urticaria, including omalizumab, failed to show a clinical benefit. Finally, ketotifen was tried, and unexpectedly reduced symptoms significantly. Ketotifen may thus represent a therapeutic option in patients with treatment-resistant vibratory angio-oedema.
AB - Vibratory angio-oedema is a rare form of physical urticaria characterized by pruriginous weals and angio-oedema at the site of exposure to vibration. Severe treatment-resistant disease can occur, and is associated with significant disability. Therapy with omalizumab, a monoclonal IgG anti-IgE antibody, has been shown to be successful in several types of physical urticaria. We report a patient with vibratory angio-oedema for whom all standard treatments for urticaria, including omalizumab, failed to show a clinical benefit. Finally, ketotifen was tried, and unexpectedly reduced symptoms significantly. Ketotifen may thus represent a therapeutic option in patients with treatment-resistant vibratory angio-oedema.
UR - http://www.scopus.com/inward/record.url?scp=84873745170&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2230.2012.04430.x
DO - 10.1111/j.1365-2230.2012.04430.x
M3 - Article
C2 - 22731986
AN - SCOPUS:84873745170
SN - 0307-6938
VL - 38
SP - 151
EP - 153
JO - Clinical and Experimental Dermatology
JF - Clinical and Experimental Dermatology
IS - 2
ER -